OncRef

Clinical Trial: NCT06131398

A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors

Status:

COMPLETED

Phase:

Phase 1

Lead Sponsor:Amgen
Information Provided By:Amgen
Last Update Posted:2026-08-11

Study Overview

Brief Summary

The primary objectives of this study are to:

  • Evaluate the safety and tolerability of AMG 355 as monotherapy and in combination with pembrolizumab in participants with advanced solid tumors
  • Determine the recommended phase 2 dose and the maximum tolerated dose for AMG 355 as monotherapy and in combination with pembrolizumab in participants with advanced solid tumors.

Official Title

A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 355 as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

Conditions

Advanced Solid Tumors

Intervention / Treatment

  • Drug: AMG 355
  • Drug: Pembrolizumab

Other Study ID Numbers

  • 20220028

Start Date (Actual)

2024-03-07

Primary Completion Date (Actual)

2026-07-22

Study Completion Date (Actual)

2026-07-22

Enrollment (Actual)

77

Study Type

Interventional

Phase

Phase 1